Objectives: A total of 15 men who died of prostate cancer had cT1/2 biopsy Gleason score ≤6 prostate cancer at prevalence screening in the European Randomized study of Screening for Prostate Cancer Rotterdam. Our objective was to explain (part of) these prostate cancer deaths by undergrading with the classical Gleason score. Methods: Biopsy specimens of 98 men with classical Gleason score ≤6 or 3 + 4 = 7 at prevalence screening in the European Randomized study of Screening for Prostate Cancer Rotterdam were retrospectively reviewed by two pathologists using the International Society of Urological Pathology 2014 modified Gleason score. These 98 men included 15 men with cT1/2 classical Gleason score ≤6 who died of prostate cancer (cases) and 83 randomly selected men with classical Gleason score ≤6 or 3 + 4 = 7 (controls). The primary outcome was the reclassification rate from classical Gleason score ≤6 to modified classical Gleason score 3 + 4 = 7 (grade group 2) stratified for prostate cancer death. The secondary outcome was the rate of cribriform/intraductal carcinoma in Gleason score-reclassified men stratified for prostate cancer death. Results: A total of 79 out of 98 men had classical Gleason score ≤6 prostate cancer. A total of eight out of 15 (53%) prostate cancer deaths with classical Gleason score ≤6 were reclassified to modified Gleason score 3 + 4 = 7, compared with 16 out of 64 (25%) men with non-fatal prostate cancer (P = 0.017). A total of five out of eight (63%) Gleason score-reclassified men with fatal prostate cancer had cribriform/intraductal carcinoma, compared with two out of 16 (13%) Gleason score-reclassified men with non-fatal prostate cancer (P = 0.011). Conclusions: Part of the prostate cancer deaths with Gleason score ≤6 at prevalence screening in the European Randomized study of Screening for Prostate Cancer Rotterdam could be explained by biopsy undergrading. The present study confirms that the International Society of Urological Pathology 2014 modified Gleason score is more accurate for prognostic assessment based on prostate biopsy than the classical Gleason score.
Introduction
PSA-based PCa screening in the ERSPC Rotterdam resulted in a 32% PCa-specific mortality reduction in the core age group of 55-69 years. 1 During a median follow up of 12.8 years, a total of 151 PCa deaths occurred in the screening arm. 1 Remarkably, 22 (14.6%) of these 151 PCa deaths were diagnosed with GS ≤6 PCa on sextant prostate biopsy in the prevalence (first) screening round. A total of 15 (68%) out of these 22 fatal PCa with GS ≤6 at prevalence screening had cT1/2-stage disease, and thus were classified as low-risk. As GS ≤6 PCa on RP is very unlikely to metastasize, a high-grade tumor component not detected by biopsy is most likely responsible for PCa death in these men. [2] [3] [4] The high-grade tumor component could either have been missed as a result of insufficient tumor sampling by random sextant biopsy or as a result of undergrading of the biopsy specimens. Apart from human reading error, undergrading could have been caused by insufficiencies in the cGS, used to grade the biopsy specimens in the prevalence screening round of the ERSPC Rotterdam (1993-1999).
In 2005, the ISUP mGS was adopted. 5 Biopsy grading according to the ISUP 2005 mGS tends to decrease the number of GS ≤6 PCa and increase the number of GS 3 + 4 = 7 PCa. [6] [7] [8] [9] Although challenged by some, it has been shown that prognostic prediction based on prostate biopsy is more accurate with the ISUP 2005 mGS as compared with the cGS. [9] [10] [11] [12] [13] Recently, an updated GS was proposed based on the ISUP consensus conference in November 2014. 14, 15 The ISUP 2014 mGS significantly outperforms the ISUP 2005 mGS in terms of prognostic prediction. 16 Hypothetically, part of the PCa deaths with biopsy GS ≤6 at prevalence screening in the ERSPC Rotterdam could be explained by undergrading with the cGS. In the present study, we compared the reclassification rate from biopsy cGS ≤6 to ISUP 2014 mGS 3 + 4 = 7 (grade group 2) at prevalence screening in men who did or did not die of PCa to assess the rate of PCa deaths with GS ≤6 that could be explained by biopsy undergrading.
Methods

ERSPC Rotterdam
The study population and protocol of the ERSPC Rotterdam have previously been described in detail. 17 Starting in 1993, a total of 42.376 men aged 54-74 years were randomized to a screening or control arm in a 1:1 ratio. In the screening arm, men were offered PSA testing with a 4-year interval until the age of 75 years. Random sextant biopsy was initially offered to men with a PSA ≥4.0 ng/mL and/or abnormal DRE, later on it was offered to men with a PSA ≥3.0 ng/mL. The PCaspecific mortality was the primary end-point of the ERSPC. The cause of death was assessed for all men with a PCa diagnosis (both in and outside the screening protocol) through linkage with the national cancer registry and subsequent patient chart review by an independent monitoring committee. Death as a result of a PCa intervention-related complication was classified as PCa death according to the Causes of Death Committee protocol. The study was approved by the institutional ethical review board (MEC 1994-152) , and written informed consent with guarantee of confidentiality was obtained from the participants. For the current analysis, a follow up until the end of 2012 was used, as follow up and cause-of-death assessment was complete up to and including 2012.
Retrospective consensus review with the ISUP 2014 mGS
Until the end of 2012, a total of 15 men diagnosed with cT1/ 2 cGS ≤6 PCa in the prevalence screening round of the ERSPC Rotterdam (1993-1999) died of PCa.
1 These men were selected as cases for the current case-control study. Subsequently, a computer-assisted random selection was performed of 85 controls out of all other men diagnosed at prevalence screening with cGS ≤6 or 3 + 4 = 7 PCa (n = 963). The randomly selected control group consisted of both men with cGS ≤6 and men with cGS 3 + 4 = 7, so that the uropathologists knew they would not solely review biopsy specimens originally graded as cGS ≤6. In 98 out of the 100 selected men, the biopsy specimens were available for pathological review. In the two remaining men, the biopsy specimens were no longer present in our biorepository. The 98 biopsy specimens, originally scored using the cGS, were reviewed independently by two expert uropathologists (THK, GJL) for grading with the ISUP 2014 mGS. One of the uropathologists (THK) originally graded all biopsy specimens during the prevalence screening round with the cGS. Both pathologists were blinded for the original cGS (6 or 3 + 4 = 7) and patient outcome during follow up after the PCa diagnosis. After the pathologists independently graded all biopsy specimens, consensus on the mGS was reached in all cases after common re-evaluation and open discussion.
Statistical analysis
Clinical patient characteristics were compared between men who did or did not die of PCa. The interobserver agreement between the pathologists for the mGS (i.e. 6 or ≥3 + 4 = 7) was assessed both proportionally and with the Cohen's j statistic. The rates of reclassification from cGS ≤6 to mGS 3 + 4 = 7 (grade group 2) were compared in all 98 men after stratification for PCa death, BCR after initial treatment by RP or RT and the development of PCa metastasis during follow up until the end of 2012. BCR was defined as two consecutive PSA measurements ≥0.2 ng/mL with an interval of 2-3 months after RP, or a PSA ≥2.0 ng/mL above the PSA nadir after RT. The distribution of the grade 4 growth patterns were compared between the GS upgraded men who died or did not die of PCa to determine a potentially higher rate of cribriform and/or IDC growth in men with fatal disease. Cribriform growth and IDC were combined for analysis; as both entities are equally associated with poor clinical outcome, they often coexist, and their morphological distinction is often difficult. 18 Intergroup comparison of continuous and categorical data was carried out using the Mann-Whitney U-test and v 2 -test, respectively. Statistical tests were two-sided, with the criterion of significance set at P < 0.05. SPSS for Windows (Version 21.0; IBM, Armonk, NY, USA) was used for the statistical analysis.
Results
Patient characteristics at PCa diagnosis
The patient characteristics at diagnosis of the 98 selected men stratified for PCa death are shown in Table 1 . After stratification for PCa death, there were no statistically significant differences in median age (67.7 vs 68.8 years), the proportion of men with a suspicious DRE (52% vs 53%) and the proportion of men who received active treatment with curative intent (91% vs 94%). The median serum PSA at diagnosis was significantly higher in men with fatal PCa (7.6 vs 5.0 ng/mL, P = 0.007). Furthermore, men with fatal PCa had a higher number of positive cores at sextant biopsy, and a higher maximum percentage of cancer core involvement. Although not statistically significant, the proportion of men receiving immediate RT was higher in the fatal PCa group (65% vs 42%), possibly reflecting higher-risk disease. In the non-fatal PCa group, five men received delayed active treatment after a median period of 3.5 years (IQR 1.3-4.2) of WW: four men received RT, while one man was treated by RP. Only one out of the 15 men with cT1/2 cGS ≤6 and PCa death during a median follow up of 13.7 years (IQR 10.1-15.3) did not receive active treatment. Table S1 shows the (not-revised) prostatectomy cGS of all 40 men who received RP at diagnosis.
Consensus review with the ISUP 2014 mGS
The expert pathologists individually agreed on the ISUP 2014 mGS (i.e. 6 or ≥3 + 4 = 7) in 84 out of 98 (86%) men. There was substantial interobserver agreement with a Cohen's j of 0.70. After consensus was reached on the mGS in the discordant cases, a total of 24 out of 79 (30%) men were upgraded from biopsy cGS ≤6 to mGS 3 + 4 = 7 PCa (grade group 2). Biopsy revision of the 19 men with cGS 3 + 4 = 7 yielded downgrading to mGS 6 (grade group 1) in two out of 19 (10.5%) men and upgrading to mGS 4 + 3 = 7 (grade group 3) in two out of 19 (10.5%) men.
GS reclassification rates stratified for BCR, metastases and PCa death
After stratification for PCa death, as shown in Table 2 , the GS reclassification rate from cGS ≤6 to mGS 3 + 4 = 7 was significantly higher in men with fatal PCa (53%) in comparison with men who did not die of PCa (25%; P = 0.017). Table 3 shows that 26 out of 85 (31%) men who were treated at diagnosis developed BCR during a median PSA follow up of 8.9 years (IQR 5.6-12.9). Although statistically insignificant, the GS reclassification rate was higher in men who developed BCR (40%) as compared with men who did not (26%). The GS reclassification rate was also higher in men who developed PCa metastasis (46%) as compared with men who did not (27%; P = 0.129). As two men died of a PCa intervention-related complication before clinical metastases occurred, the number of PCa deaths (17) was higher than the number of men who developed PCa metastases (15) . One man died of a cardiovascular complication that was initiated by RP. The other man had castration-resistant PCa without clinical metastases, but died after an endoscopic intervention for refractory hematuria caused by radiation cystitis. Table 4 shows the distribution of the grade 4 growth patterns in all men with mGS ≥3 + 4 = 7 (grade group 2). The most common growth patterns in GS-reclassified men were fused glands (17/24 men) and ill-formed glands (15/24 men). All men with IDC also had cribriform growth in their biopsy specimen. GS-reclassified men with fatal PCa had significantly more cribriform/IDC growth as compared with men who did not die of PCa (63% vs 13%, P = 0.011).
Distribution of grade 4 growth patterns in GS reclassified men
Discussion
Although GS ≤6 PCa on RP is very unlikely to metastasize, [2] [3] [4] a substantial number of 15 PCa deaths in the ERSPC Rotterdam were men diagnosed at prevalence screening with cT1/2 biopsy cGS ≤6 PCa.
1 A high-grade tumor component not detected by (initial) pathological review of the biopsy specimens is most likely to be responsible for the PCa death in these men. As all but one of these men received active treatment, the main explanations for the "missed" high-grade tumor component could either be insufficient tumor sampling by sextant biopsy or undergrading of the biopsy specimens.
In the present study, we showed that the reclassification rate from cGS ≤6 to mGS 3 + 4 = 7 (grade group 2) was significantly higher in men with fatal PCa (53%) compared with men who did not die of PCa (25%). This shows that a substantial part of the PCa deaths with GS ≤6 at prevalence screening in the ERSPC Rotterdam could be explained by biopsy undergrading. In the ISUP 2005 mGS and subsequently the ISUP 2014 mGS, the definition of Gleason pattern 3 was further specified, moving some architectural patterns from Gleason pattern 3 to the pattern 4 category, and as a consequence the definition of pattern 4 is expanded, causing a shift of PCa graded as biopsy GS ≤6 towards GS 3 + 4 = 7.
14,19 After revision of biopsy specimens, upgrading to ISUP 2005 mGS 3 + 4 = 7 occurs in 19-45% of men originally diagnosed with cGS ≤6. [6] [7] [8] [9] The upgrading rate of 30% in the present study is in line with these previous findings. To our knowledge, we are the first to report on a higher GS upgrading rate in men who died of PCa. Although statistically not significant, the GS upgrading rate also tended to be higher in the present study in men who developed BCR and PCa metastasis. Previous studies reported on the superior prognostic prediction of the biopsy ISUP 2005 mGS as compared with the cGS, both for BCR after RP 9-11 and for PCa-specific survival in men on WW. 12 Recent evidence suggests further improvement of prognostic prediction with the biopsy ISUP 2014 mGS. 16 The findings of the present study support that the ISUP 2014 mGS is a more accurate tool for prognostic assessment based on prostate biopsy than the cGS. As the main goal of the present study was to explain (part of) the PCa deaths in the ERSPC Rotterdam with GS ≤6 at prevalence screening by undergrading with the cGS, our study was not designed for a comparison between grading with the ISUP 2005 mGS and the ISUP 2014 mGS.
Although enabling a more accurate prognostic prediction, upfront grading with the ISUP 2014 mGS probably would not have affected the PCa death rate in our cohort from the pre-active surveillance era, as 90 out of 98 (92%) men received active treatment with curative intent. Nowadays, active surveillance is increasingly implemented in biopsy GS ≤6 PCa. As the oncological safety of active surveillance in men with (limited) Gleason pattern 4 is not yet proven, it is essential to select only those men with low-grade disease. 20 The mGS, which has been implemented ever since the rise of active surveillance as a treatment modality, probably allows a superior patient selection for active surveillance as compared with the cGS. In the near future, patients with (limited) Gleason pattern 4 could be selected for active surveillance based on the grade 4 growth pattern. Cribriform growth and IDC in prostate biopsy have been shown to be equally associated with a poor cancer-specific survival as compared with men without cribriform/IDC growth. 18 The present study confirmed cribriform/IDC growth as a risk factor for PCa death, with a higher rate of cribriform/IDC growth in GS-reclassified men with fatal PCa. Cribriform growth and IDC were combined for analysis, as both entities often coexist and can be hard to distinguish. Combining cribriform growth and IDC does not alter the prognostic value, and morphological distinction between the separate entities by additional immunohistochemistry is no longer required. Besides biopsy undergrading, undersampling by sextant biopsy is probably the most important cause of "missed" high-grade tumor components in fatal PCa with GS ≤6 at prevalence screening. Extended systematic biopsy core schemes increase the PCa detection rate by a factor of 1.3.
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Systematic biopsy insufficiently samples anterior tumors, not only leading to underdetection, but also undergrading of tumors. 22, 23 Upgrading of biopsy GS ≤6 on RP occurs in approximately 40% of cases. 24, 25 In the present cohort, a total of seven men with cT1/2 cGS ≤6 and PCa death were not reclassified with the mGS. Three of these men were treated by RP. As shown in Table S1 , all three had a high-grade tumor component in the RP specimen (cGS 5 + 4, 3 + 5 and 4 + 3), indicating insufficient tumor sampling by random sextant biopsy. The development of a high-grade tumor component after the initial diagnosis during WW could not be responsible for the PCa death in the 15 men with cT1/2 cGS ≤6, as all but one of these men received active treatment (5 RP and 9 RT).
Besides grading with the ISUP 2014 mGS, GS upgrading could be caused by a general shift upwards of the perception of patterns (Gleason inflation) after the introduction of the mGS. Furthermore, pathological (double reading) revision of the biopsy specimens with correction of initial diagnostic errors could also yield GS upgrading. Highly variable levels of intraobserver (43-78%) and interobserver (36-81%) agreement of the GS have been reported. [26] [27] [28] The 86% interobserver agreement in the present study is in line with the approximately 80% interobserver agreement found in most studies using the mGS. 10 In the present study, consensus review was only carried out for the mGS. However, we would not expect a variation of interobserver cGS variability between subgroups after stratification for PCa death, nor would we expect a variation in Gleason inflation. Thus, the difference in the rate of upgrading to mGS 3 + 4 = 7 between men who did and did not die of PCa in our cohort is most likely primarily based on undergrading with the cGS.
The strength of the present study lies in the double reading of the biopsy specimens and the accurate long-term follow up. However, as we only had follow up until the end of 2012, more PCa deaths might have occurred in our cohort afterwards. The present study was also limited by the fact that our small cohort included only a fraction of all cGS 3 + 3 and 3 + 4 PCa in the prevalence screening round of the ERSPC Rotterdam. Finally, the sextant prostate biopsy carried out in our cohort detects less (significant) PCa as compared with extended biopsy core schemes used in current clinical practice.
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Editorial Comment
Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam
The recommendations for grading prostatic adenocarcinoma have undergone a series of changes over the past decade under the auspices of the International Society of Urological Pathology (ISUP). The aim has been to better identify aggressive disease and predict tumor phenotype from biopsy samples. One of the limitations of biopsy grading is that only a small portion of the tumor is sampled by core biopsies. Consequently, the accurate identification of cancer patterns on needle biopsy that best signal aggressive behavior is pivotal.
A recent important insight into prostate cancer biology is that cribriform patterns show a high likelihood of tumor progression. In an early study we analyzed the aggressiveness of patterns of Gleason grade (GG) 3 and 4 by microdissection, ploidy measurement and planimetry. What was then considered cribriform GG 3 had the same rate of non-diploid cancer as GG 4 (40.0% and 40.9%, respectively), whereas non-cribriform GG 3 was non-diploid in just 12.4% of cases. 1 Later studies have confirmed that cribriform patterns of prostatic adenocarcinoma herald aggressive behavior, and should be classified as high-grade cancer. This has been factored into recent guidelines for grading, which have contributed to a stricter definition of Gleason score (GS) 6 (ISUP grade 1). 2 As a consequence of this, it has been shown that reporting of GS 3 + 3 = 6 decreased from 30.2% to 18.0% of cases in one series using ISUP 2005 modified grading compared with conventional GG. 3 It has been argued that cancer with GS 6 or lower in radical prostatectomy specimens is unable to metastasize, although other studies have shown lymph node metastases in up to 3% of GS 6 tumors. 4 It is not axiomatic that the same would be true on needle biopsy. First, only a small number of cases (7.6%) are now reported as GS ≤6 on radical prostatectomy specimens, which shows that low-grade cancer in these specimens is now restricted to a small group of tumors with very bland morphology. 5 Second, if cancer of GS 6 is detected by biopsy, there might still be cancer of a higher grade elsewhere in the prostate, and aggressive disease cannot be completely ruled out. This somewhat limits the utility of GS 6 on needle biopsy as a criterion for deferred treatment.
In an elegant study, Alberts et al. has addressed these issues by allowing pathologists to blindly review biopsies with GS ≤6 and fatal cancer in the ERSPC cohort, together with other biopsies of non-fatal cancer. 6 They confirmed that the ISUP 2014 grading better predicts fatal disease, as 53% of fatal cancers were upgraded at biopsy review using contemporary criteria. Interestingly, their study shows that cribriform patterns (cribriform invasive cancer or intraductal cancer) portend a particularly sinister outcome, with as many as 63% of reclassified fatal GS 6 cancers having a cribriform architecture. It might thus be timely to consider more critically the significance of cribriform patterns in future revisions of the grading schedule.
It should also be kept in mind that even after blinded review according to contemporary criteria, 47% of fatal biopsy GS 6 cancers remained classified as GS 6. This might be explained by sampling error, but could also show that there could be a small subset of truly aggressive tumors with deceptively bland morphology. Thus, additional biomarkers for prediction of the true biological nature of these tumors are required.
